Aerovate Therapeutics, Inc. is a biopharmaceutical company based in Waltham, MA, dedicated to developing innovative therapies for rare cardiopulmonary diseases. With a passionate team of experts in drug development and cardiopulmonary disease, Aerovate is focused on addressing the underlying drivers of diseases like Pulmonary Arterial Hypertension (PAH) through their lead program, AV-101, a dry powder inhaled formulation of imatinib. Their goal is to redefine treatment options and help individuals regain control over their health and lives.
Driven by a singular focus on improving the lives of people living with rare cardiopulmonary diseases, Aerovate is committed to advancing novel therapies from drug development to commercialization. They are actively seeking dynamic and motivated individuals to join their team of problem-solvers and experts in the field. By leveraging unique skills and talents, individuals can make a significant difference in the lives of those affected by these debilitating diseases.
Generated from the website